Overview

Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Enrolled patients will be recruited to two parallel groups during therapy for Hepatitis C. Patients in the first one will receive a patient assistance program, and patients in the second group will not. All patients will receive PegIntron and Rebetol according to label.
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Interferon-alpha
Peginterferon alfa-2b
Ribavirin